<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group|1</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">9052419</article-id><article-id pub-id-type="pmc">2063294</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Papamichael</surname><given-names>D.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Gallagher</surname><given-names>C. J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Oliver</surname><given-names>R. T.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Johnson</surname><given-names>P. W.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Waxman</surname><given-names>J.</given-names></name></contrib></contrib-group><aff>Department of Medical Oncology, St Bartholomew's Hospital, West Smithfield, London, UK.</aff><pub-date pub-type="ppub"><year>1997</year></pub-date><volume>75</volume><issue>4</issue><fpage>606</fpage><lpage>607</lpage><abstract><p>Fourteen patients with previously treated, locally advanced/metastatic transitional cell carcinoma (TCC) of the bladder or ureter received paclitaxel at a dose of 200 mg m-2 administered as a 3-h infusion every 21 days. The activity of paclitaxel in this group of patients was modest. The response rates were one partial response (PR) (7%) and three stable disease (SD). There were two early deaths.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00181-0144.tif" xlink:title="scanned-page" xlink:role="606" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00181-0145.tif" xlink:title="scanned-page" xlink:role="607" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

